143 related articles for article (PubMed ID: 21143702)
21. Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor.
Choi KC; Kwak SE; Kim JE; Sheen SH; Kang TC
Neurosci Lett; 2009 Oct; 463(3):182-7. PubMed ID: 19647039
[TBL] [Abstract][Full Text] [Related]
22. Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumour cells negatively correlates with proliferation, while vascular SPARC expression is associated with patient survival.
Capper D; Mittelbronn M; Goeppert B; Meyermann R; Schittenhelm J
Neuropathol Appl Neurobiol; 2010 Apr; 36(3):183-97. PubMed ID: 20132490
[TBL] [Abstract][Full Text] [Related]
23. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Waltregny D; North B; Van Mellaert F; de Leval J; Verdin E; Castronovo V
Eur J Histochem; 2004; 48(3):273-90. PubMed ID: 15590418
[TBL] [Abstract][Full Text] [Related]
24. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
25. Patterns of expression of TSC-22 protein in astrocytic gliomas.
Shostak KO; Dmitrenko VV; Vudmaska MI; Naidenov VG; Beletskii AV; Malisheva TA; Semenova VM; Zozulya YP; Demotes-Mainard J; Kavsan VM
Exp Oncol; 2005 Dec; 27(4):314-8. PubMed ID: 16404353
[TBL] [Abstract][Full Text] [Related]
26. Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells.
Ajamian F; Salminen A; Reeben M
Neurosci Lett; 2004 Jul; 365(1):64-8. PubMed ID: 15234474
[TBL] [Abstract][Full Text] [Related]
27. Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study.
Giannopoulou E; Ravazoula P; Kalofonos H; Makatsoris T; Kardamakis D
In Vivo; 2006; 20(3):421-5. PubMed ID: 16724682
[TBL] [Abstract][Full Text] [Related]
28. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
29. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.
Horiuchi M; Morinobu A; Chin T; Sakai Y; Kurosaka M; Kumagai S
J Rheumatol; 2009 Aug; 36(8):1580-9. PubMed ID: 19531758
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development.
MacDonald JL; Roskams AJ
Dev Dyn; 2008 Aug; 237(8):2256-67. PubMed ID: 18651664
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2.
Grégoire S; Xiao L; Nie J; Zhang X; Xu M; Li J; Wong J; Seto E; Yang XJ
Mol Cell Biol; 2007 Feb; 27(4):1280-95. PubMed ID: 17158926
[TBL] [Abstract][Full Text] [Related]
32. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
Müller BM; Jana L; Kasajima A; Lehmann A; Prinzler J; Budczies J; Winzer KJ; Dietel M; Weichert W; Denkert C
BMC Cancer; 2013 Apr; 13():215. PubMed ID: 23627572
[TBL] [Abstract][Full Text] [Related]
34. Elevated immunoreactivity against class I histone deacetylases in adenomyosis.
Liu X; Nie J; Guo SW
Gynecol Obstet Invest; 2012; 74(1):50-5. PubMed ID: 22539030
[TBL] [Abstract][Full Text] [Related]
35. Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.
Elsir T; Eriksson A; Orrego A; Lindström MS; Nistér M
J Neuropathol Exp Neurol; 2010 Feb; 69(2):129-38. PubMed ID: 20084020
[TBL] [Abstract][Full Text] [Related]
36. Association between laminin-8 and glial tumor grade, recurrence, and patient survival.
Ljubimova JY; Fugita M; Khazenzon NM; Das A; Pikul BB; Newman D; Sekiguchi K; Sorokin LM; Sasaki T; Black KL
Cancer; 2004 Aug; 101(3):604-12. PubMed ID: 15274074
[TBL] [Abstract][Full Text] [Related]
37. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Krusche CA; Wülfing P; Kersting C; Vloet A; Böcker W; Kiesel L; Beier HM; Alfer J
Breast Cancer Res Treat; 2005 Mar; 90(1):15-23. PubMed ID: 15770522
[TBL] [Abstract][Full Text] [Related]
39. Ezrin expression in tissue microarray of primary and recurrent gliomas.
Tynninen O; Carpén O; Jääskeläinen J; Paavonen T; Paetau A
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):472-7. PubMed ID: 15488023
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of Cx43 in astrocytic tumors.
Pu P; Xia Z; Yu S; Huang Q
Clin Neurol Neurosurg; 2004 Dec; 107(1):49-54. PubMed ID: 15567553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
